Velpanat (400 mg Sofosbuvir / 100 mg Velpatasvir)

NATCO PHARMA LIMITED (INDIA)

“Velpanat” contains the Drugs / Molecules called “Sofosbuvir & Velpatasvir”.

Velpanat has high overall cure rates of 99% for GT2 patients† and 95% for GT3 patients. Velpanat was also found to be highly effective in patients with GT1, GT4, GT5 and GT6, with overall cure rates ranging from 97–100%.

Indication

Velpanat is helpful for treatment of all Hepatitis C adults who are suffering from genotype 1-6 chronic hepatitis C virus.

Note

SIDE EFFECTS :

  • Common side effects include muscle pains, headache, nausea, rash, diarrhea, insomnia and cough.
  • More severe reactions are connected with allergic reactions to the medications and cardiovascular problems.

INTERACTIONS :

  • For the HIV combination Efavirenz / Emtricitabine / Tenofovir, which reduces the area under the curve (AUC) of Velpatasvir by about 50%, and the CYP3A4 and Pgp inducer Rifampicin, which reduces its AUC by about 80%, rendering it likely ineffective.
  • Digoxin is eliminated by Pgp; its AUC is increased by about 30% in combination with Velpatasvir and Sofosbuvir.
  • Substances that reduce gastric acid, such as Antacids, H2 blockers, and Proton pump inhibitors, reduce Velpatasvir AUC by 20–40%.

OVERDOSE :

  • Do not use more than prescribed dose.
  • If you suspect you may have overdosed, call your healthcare provider.
  • Do not take extra dose to make up for the missed dose.

Precaution

  • Velpanat is a prescription drug and should be used under proper medical guidance and advice.
  • Caution should be exercised in patients with history of stomach problem, liver, kidney, or heart disease during pregnancy and breastfeeding.